Second generation drug-eluting stents versus bare-metal stents for percutaneous coronary intervention of the proximal left anterior descending artery: An analysis of the BASKET-PROVE I and II trials

Fernanda Marinho Mangione; Tor Biering-Sørensen; Kotaro Nochioka; Tannas Jatene; Odilson Marcos Silvestre; Kim Wadt Hansen; Rikke Sørensen; Jan Skov Jensen; Peter Godsk Jorgensen; Raban Jeger; Christoph Kaiser; Matthias Pfisterer; Søren Galatius

doi:10.1002/ccd.27200

Second generation drug-eluting stents versus bare-metal stents for percutaneous coronary intervention of the proximal left anterior descending artery: An analysis of the BASKET-PROVE I and II trials

Fernanda Marinho Mangione, Tor Biering-Sørensen, Kotaro Nochioka, Tannas Jatene, Odilson Marcos Silvestre, Kim Wadt Hansen, Rikke Sørensen, Jan Skov Jensen, Peter Godsk Jorgensen, Raban Jeger, Christoph Kaiser, Matthias Pfisterer, Søren Galatius

2 Citations (Scopus)

Abstract

OBJECTIVES: To compare mid-term outcomes between patients undergoing proximal left anterior descending artery (LAD) percutaneous coronary intervention (PCI) with second generation drug-eluting stent (DES) or bare-metal stent (BMS).

BACKGROUND: PCI with BMS and first-generation DES have shown to be safe options for the treatment of proximal LAD stenosis, however associated with considerable reintervention rates. Overall, second-generation DES has proven to be superior to BMS and first-generation DES, nevertheless, its effect for proximal LAD PCI has not previously been reported.

METHODS: We analyzed 2-year outcomes of 1,100 patients from the BASKET-PROVE I and II trials, referred for proximal LAD PCI with second generation DES (n = 680) or BMS (n = 420).

RESULTS: The cumulative 2-year incidence of major adverse cardiac events (MACE, composite of cardiac death, myocardial infarction (MI) and target vessel revascularization (TVR)) was lower in second generation DES than in BMS treated patients (7.3% vs. 12.3%; HR 0.57, 95% CI 0.39/0.85), mainly driven by a reduced rate of TVR (3.7% vs. 10.0%; HR 0.35, CI 0.21/0.58). No difference was found in cardiac death (1.9% vs. 1.9%; HR 1.01, CI 0.42/2.44) and MI (4.4% vs. 4.7%; HR 0.93, CI 0.53/1.64). The benefit of DES use seemed to be more prominent in female patients with a reduction in MACE (P for interaction = 0.025).

CONCLUSIONS: In patients with proximal LAD stenosis, treatment with second-generation DES was associated with reduced 2-year rates of adverse cardiac events and TVR compared to BMS, with reintervention rates similar to those earlier reported from bypass surgery.

Original language	English
Journal	Catheterization and Cardiovascular Interventions
Volume	91
Issue number	5
Pages (from-to)	867-873
ISSN	1522-1946
DOIs	https://doi.org/10.1002/ccd.27200
Publication status	Published - 1 Apr 2018

Keywords

Aged
Coronary Artery Disease/diagnostic imaging
Coronary Stenosis/diagnostic imaging
Drug Therapy, Combination
Drug-Eluting Stents
Female
Humans
Male
Metals
Middle Aged
Myocardial Infarction/etiology
Percutaneous Coronary Intervention/adverse effects
Platelet Aggregation Inhibitors/therapeutic use
Prosthesis Design
Randomized Controlled Trials as Topic
Risk Factors
Stents
Time Factors
Treatment Outcome

Access to Document

10.1002/ccd.27200

Cite this

Mangione, F. M., Biering-Sørensen, T., Nochioka, K., Jatene, T., Silvestre, O. M., Hansen, K. W., Sørensen, R., Jensen, J. S., Jorgensen, P. G., Jeger, R., Kaiser, C., Pfisterer, M., & Galatius, S. (2018). Second generation drug-eluting stents versus bare-metal stents for percutaneous coronary intervention of the proximal left anterior descending artery: An analysis of the BASKET-PROVE I and II trials. Catheterization and Cardiovascular Interventions, 91(5), 867-873. https://doi.org/10.1002/ccd.27200

Second generation drug-eluting stents versus bare-metal stents for percutaneous coronary intervention of the proximal left anterior descending artery : An analysis of the BASKET-PROVE I and II trials. / Mangione, Fernanda Marinho; Biering-Sørensen, Tor; Nochioka, Kotaro et al.

In: Catheterization and Cardiovascular Interventions, Vol. 91, No. 5, 01.04.2018, p. 867-873.

Research output: Contribution to journal › Journal article › Research › peer-review

Mangione, FM, Biering-Sørensen, T, Nochioka, K, Jatene, T, Silvestre, OM, Hansen, KW, Sørensen, R, Jensen, JS, Jorgensen, PG, Jeger, R, Kaiser, C, Pfisterer, M & Galatius, S 2018, 'Second generation drug-eluting stents versus bare-metal stents for percutaneous coronary intervention of the proximal left anterior descending artery: An analysis of the BASKET-PROVE I and II trials', Catheterization and Cardiovascular Interventions, vol. 91, no. 5, pp. 867-873. https://doi.org/10.1002/ccd.27200

Mangione FM, Biering-Sørensen T, Nochioka K, Jatene T, Silvestre OM, Hansen KW et al. Second generation drug-eluting stents versus bare-metal stents for percutaneous coronary intervention of the proximal left anterior descending artery: An analysis of the BASKET-PROVE I and II trials. Catheterization and Cardiovascular Interventions. 2018 Apr 1;91(5):867-873. doi: 10.1002/ccd.27200

Mangione, Fernanda Marinho ; Biering-Sørensen, Tor ; Nochioka, Kotaro et al. / Second generation drug-eluting stents versus bare-metal stents for percutaneous coronary intervention of the proximal left anterior descending artery : An analysis of the BASKET-PROVE I and II trials. In: Catheterization and Cardiovascular Interventions. 2018 ; Vol. 91, No. 5. pp. 867-873.

@article{cc6f3fec49c24c38a70430a16f6925b1,

title = "Second generation drug-eluting stents versus bare-metal stents for percutaneous coronary intervention of the proximal left anterior descending artery: An analysis of the BASKET-PROVE I and II trials",

abstract = "OBJECTIVES: To compare mid-term outcomes between patients undergoing proximal left anterior descending artery (LAD) percutaneous coronary intervention (PCI) with second generation drug-eluting stent (DES) or bare-metal stent (BMS).BACKGROUND: PCI with BMS and first-generation DES have shown to be safe options for the treatment of proximal LAD stenosis, however associated with considerable reintervention rates. Overall, second-generation DES has proven to be superior to BMS and first-generation DES, nevertheless, its effect for proximal LAD PCI has not previously been reported.METHODS: We analyzed 2-year outcomes of 1,100 patients from the BASKET-PROVE I and II trials, referred for proximal LAD PCI with second generation DES (n = 680) or BMS (n = 420).RESULTS: The cumulative 2-year incidence of major adverse cardiac events (MACE, composite of cardiac death, myocardial infarction (MI) and target vessel revascularization (TVR)) was lower in second generation DES than in BMS treated patients (7.3% vs. 12.3%; HR 0.57, 95% CI 0.39/0.85), mainly driven by a reduced rate of TVR (3.7% vs. 10.0%; HR 0.35, CI 0.21/0.58). No difference was found in cardiac death (1.9% vs. 1.9%; HR 1.01, CI 0.42/2.44) and MI (4.4% vs. 4.7%; HR 0.93, CI 0.53/1.64). The benefit of DES use seemed to be more prominent in female patients with a reduction in MACE (P for interaction = 0.025).CONCLUSIONS: In patients with proximal LAD stenosis, treatment with second-generation DES was associated with reduced 2-year rates of adverse cardiac events and TVR compared to BMS, with reintervention rates similar to those earlier reported from bypass surgery.",

keywords = "Aged, Coronary Artery Disease/diagnostic imaging, Coronary Stenosis/diagnostic imaging, Drug Therapy, Combination, Drug-Eluting Stents, Female, Humans, Male, Metals, Middle Aged, Myocardial Infarction/etiology, Percutaneous Coronary Intervention/adverse effects, Platelet Aggregation Inhibitors/therapeutic use, Prosthesis Design, Randomized Controlled Trials as Topic, Risk Factors, Stents, Time Factors, Treatment Outcome",

author = "Mangione, {Fernanda Marinho} and Tor Biering-S{\o}rensen and Kotaro Nochioka and Tannas Jatene and Silvestre, {Odilson Marcos} and Hansen, {Kim Wadt} and Rikke S{\o}rensen and Jensen, {Jan Skov} and Jorgensen, {Peter Godsk} and Raban Jeger and Christoph Kaiser and Matthias Pfisterer and S{\o}ren Galatius",

note = "{\textcopyright} 2017 Wiley Periodicals, Inc.",

year = "2018",

month = apr,

day = "1",

doi = "10.1002/ccd.27200",

language = "English",

volume = "91",

pages = "867--873",

journal = "Catheterization and Cardiovascular Interventions",

issn = "1522-1946",

publisher = "JohnWiley & Sons, Inc.",

number = "5",

}

TY - JOUR

T1 - Second generation drug-eluting stents versus bare-metal stents for percutaneous coronary intervention of the proximal left anterior descending artery

T2 - An analysis of the BASKET-PROVE I and II trials

AU - Mangione, Fernanda Marinho

AU - Biering-Sørensen, Tor

AU - Nochioka, Kotaro

AU - Jatene, Tannas

AU - Silvestre, Odilson Marcos

AU - Hansen, Kim Wadt

AU - Sørensen, Rikke

AU - Jensen, Jan Skov

AU - Jorgensen, Peter Godsk

AU - Jeger, Raban

AU - Kaiser, Christoph

AU - Pfisterer, Matthias

AU - Galatius, Søren

PY - 2018/4/1

Y1 - 2018/4/1

N2 - OBJECTIVES: To compare mid-term outcomes between patients undergoing proximal left anterior descending artery (LAD) percutaneous coronary intervention (PCI) with second generation drug-eluting stent (DES) or bare-metal stent (BMS).BACKGROUND: PCI with BMS and first-generation DES have shown to be safe options for the treatment of proximal LAD stenosis, however associated with considerable reintervention rates. Overall, second-generation DES has proven to be superior to BMS and first-generation DES, nevertheless, its effect for proximal LAD PCI has not previously been reported.METHODS: We analyzed 2-year outcomes of 1,100 patients from the BASKET-PROVE I and II trials, referred for proximal LAD PCI with second generation DES (n = 680) or BMS (n = 420).RESULTS: The cumulative 2-year incidence of major adverse cardiac events (MACE, composite of cardiac death, myocardial infarction (MI) and target vessel revascularization (TVR)) was lower in second generation DES than in BMS treated patients (7.3% vs. 12.3%; HR 0.57, 95% CI 0.39/0.85), mainly driven by a reduced rate of TVR (3.7% vs. 10.0%; HR 0.35, CI 0.21/0.58). No difference was found in cardiac death (1.9% vs. 1.9%; HR 1.01, CI 0.42/2.44) and MI (4.4% vs. 4.7%; HR 0.93, CI 0.53/1.64). The benefit of DES use seemed to be more prominent in female patients with a reduction in MACE (P for interaction = 0.025).CONCLUSIONS: In patients with proximal LAD stenosis, treatment with second-generation DES was associated with reduced 2-year rates of adverse cardiac events and TVR compared to BMS, with reintervention rates similar to those earlier reported from bypass surgery.

AB - OBJECTIVES: To compare mid-term outcomes between patients undergoing proximal left anterior descending artery (LAD) percutaneous coronary intervention (PCI) with second generation drug-eluting stent (DES) or bare-metal stent (BMS).BACKGROUND: PCI with BMS and first-generation DES have shown to be safe options for the treatment of proximal LAD stenosis, however associated with considerable reintervention rates. Overall, second-generation DES has proven to be superior to BMS and first-generation DES, nevertheless, its effect for proximal LAD PCI has not previously been reported.METHODS: We analyzed 2-year outcomes of 1,100 patients from the BASKET-PROVE I and II trials, referred for proximal LAD PCI with second generation DES (n = 680) or BMS (n = 420).RESULTS: The cumulative 2-year incidence of major adverse cardiac events (MACE, composite of cardiac death, myocardial infarction (MI) and target vessel revascularization (TVR)) was lower in second generation DES than in BMS treated patients (7.3% vs. 12.3%; HR 0.57, 95% CI 0.39/0.85), mainly driven by a reduced rate of TVR (3.7% vs. 10.0%; HR 0.35, CI 0.21/0.58). No difference was found in cardiac death (1.9% vs. 1.9%; HR 1.01, CI 0.42/2.44) and MI (4.4% vs. 4.7%; HR 0.93, CI 0.53/1.64). The benefit of DES use seemed to be more prominent in female patients with a reduction in MACE (P for interaction = 0.025).CONCLUSIONS: In patients with proximal LAD stenosis, treatment with second-generation DES was associated with reduced 2-year rates of adverse cardiac events and TVR compared to BMS, with reintervention rates similar to those earlier reported from bypass surgery.

KW - Aged

KW - Coronary Artery Disease/diagnostic imaging

KW - Coronary Stenosis/diagnostic imaging

KW - Drug Therapy, Combination

KW - Drug-Eluting Stents

KW - Female

KW - Humans

KW - Male

KW - Metals

KW - Middle Aged

KW - Myocardial Infarction/etiology

KW - Percutaneous Coronary Intervention/adverse effects

KW - Platelet Aggregation Inhibitors/therapeutic use

KW - Prosthesis Design

KW - Randomized Controlled Trials as Topic

KW - Risk Factors

KW - Stents

KW - Time Factors

KW - Treatment Outcome

U2 - 10.1002/ccd.27200

DO - 10.1002/ccd.27200

M3 - Journal article

C2 - 28722266

SN - 1522-1946

VL - 91

SP - 867

EP - 873

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

IS - 5

ER -

Second generation drug-eluting stents versus bare-metal stents for percutaneous coronary intervention of the proximal left anterior descending artery: An analysis of the BASKET-PROVE I and II trials

Abstract

Keywords

Access to Document

Fingerprint

Cite this